PROGEN  was founded in 1983 by four scientists from Heidelberg, Germany, who joined forces to manufacture and supply high quality antibodies for biomedical research. They help scientists worldwide drive biopharmaceutical and diagnostic progress to provide high-quality and reliable treatments for patients. The PROGEN team consists of bioscientists and adeno-associated virus (AAV) experts who collaborate with specialists around the world. Their products are essentials for research in science and industry. They are more than just a manufacturer of antibodies, AAV gene therapy tools, density gradient media, and phage display technologies: They strive to understand the needs of scientists to develop solutions to jointly address challenges in academic research, biotechnology and pharma. Since 2012, PROGEN has been a 100% subsidiary of the R-Biopharm AG.